Objectives:

1. Review pre-clinical data establishing the role of the microbiome in affecting response to immunotherapy (IO).
2. Review clinical evidence associating antibiotic use with inferior response to immunotherapy.
3. Discuss challenges and future directions. 

and

1. To review evidence for CTDNA assays in the clinical setting
2. To highlight barriers to more widespread use of CTDNA assays
3. To discuss possible solutions for these barriers